Understanding the Capricor Therapeutics Class Action Lawsuit
In the bustling world of biotechnology, shareholder rights are a crucial component of maintaining investor trust. Currently, Capricor Therapeutics, Inc. (NASDAQ: CAPR) is the focus of a significant class action lawsuit pertaining to allegations of securities fraud that began during the recent class period.
Details of the Allegations
The core of the allegations against Capricor involves their lead cell therapy candidate, deramiocel, which is developed to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). According to the complaint, there are serious concerns regarding the information disseminated by Capricor. The company allegedly provided investors with overly optimistic projections about the Biologics License Application (BLA) for deramiocel.
Timing of the Allegations
During the period from October 9, 2024, to July 10, 2025, defendants purportedly assured investors about the progress of the BLA, all the while concealing adverse data related to the drug's efficacy and safety from the critical Phase 2 HOPE-2 trial. These statements misled investors regarding the drug's viability, which is a critical factor for patient care in DMD.
Impact of the FDA Response
On July 11, 2025, a turning point occurred when Capricor released a statement announcing they had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). This letter indicated that the application did not fulfill necessary requirements, including the need for more clinical data and substantiating evidence of the drug's effectiveness. Following this announcement, the stock price plunged from $11.40 to $7.64 per share within a single day, reflecting the market's reaction to this unfavorable news.
Class Action Registration Details
Investors who purchased shares of Capricor during the stated period are encouraged to register for the class action lawsuit. Establishing your claim does not require being named a lead plaintiff in the class action; participation in recovery is available for all affected shareholders.
Registration Deadline
It is crucial for shareholders to act swiftly as the deadline to register is set for September 15, 2025. The Gross Law Firm is actively urging eligible shareholders to reach out as soon as possible to ensure their rights are protected.
Assurance of Representation from The Gross Law Firm
The Gross Law Firm stands as a reputable advocate for shareholders in situations involving deceit and fraud. Their mission is to recover losses incurred by investors due to misleading information or omissions by public companies. Shareholders can rest assured that their rights and interests are being addressed by a nationally recognized law firm committed to good corporate practices.
Contact Information for Further Assistance
If you believe you have a stake in this matter or require more information, contacting The Gross Law Firm is essential. They provide personalized assistance for all inquiries regarding this class action lawsuit.
Why Reach Out?
Whether you have specific questions or need guidance on the legal process, their team is ready to assist. Investors are entitled to know the details surrounding their investments and the actions necessary to safeguard their interests.
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit claims that Capricor Therapeutics provided misleading information regarding their drug, deramiocel, leading to financial losses for investors.
When is the deadline to register for the class action?
The deadline to register for the class action lawsuit is September 15, 2025.
How can I register as a shareholder?
Shareholders can register their claims through contact with The Gross Law Firm which facilitates the process.
What costs are associated with participation?
There are no costs or obligations to register and participate in the lawsuit.
Why choose The Gross Law Firm?
The Gross Law Firm is dedicated to protecting investor rights and recovering losses caused by fraudulent practices within the financial markets.
